Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome

Br J Haematol. 2020 Mar;188(5):e68-e72. doi: 10.1111/bjh.16332. Epub 2019 Nov 13.
No abstract available

Keywords: L-HES; eosinophil; hypereosinophilic syndrome; interferon alpha.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Follow-Up Studies
  • Humans
  • Hypereosinophilic Syndrome / diagnosis
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / pathology
  • Interferon-alpha / administration & dosage*
  • Interferon-alpha / adverse effects
  • Male
  • Middle Aged
  • Polyethylene Glycols / administration & dosage*
  • Polyethylene Glycols / adverse effects
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects

Substances

  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2a